MDT

86.28

-0.38%↓

A

118.38

-1.59%↓

VEEV

168.34

+1.3%↑

HQY

84.43

+1.39%↑

NEOG

9.29

-1.69%↓

MDT

86.28

-0.38%↓

A

118.38

-1.59%↓

VEEV

168.34

+1.3%↑

HQY

84.43

+1.39%↑

NEOG

9.29

-1.69%↓

MDT

86.28

-0.38%↓

A

118.38

-1.59%↓

VEEV

168.34

+1.3%↑

HQY

84.43

+1.39%↑

NEOG

9.29

-1.69%↓

MDT

86.28

-0.38%↓

A

118.38

-1.59%↓

VEEV

168.34

+1.3%↑

HQY

84.43

+1.39%↑

NEOG

9.29

-1.69%↓

MDT

86.28

-0.38%↓

A

118.38

-1.59%↓

VEEV

168.34

+1.3%↑

HQY

84.43

+1.39%↑

NEOG

9.29

-1.69%↓

Search

Guardant Health Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

85.58 0.63

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

82.91

Max

86.34

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+54.86% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.8B

11B

Ankstesnė atidarymo kaina

84.95

Ankstesnė uždarymo kaina

85.58

Naujienos nuotaikos

By Acuity

50%

50%

167 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-15 23:14; UTC

Uždarbis

Battery Maker CATL First-Quarter Net Rose on Strong Demand

2026-04-15 23:14; UTC

Uždarbis

Battery Maker CATL First Quarter Net Rose On Strong Demand

2026-04-15 17:13; UTC

Pagrindinės rinkos jėgos

Tesla Shares Rise on Completion of AI5 Chip Design Process

2026-04-15 23:39; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-15 23:35; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

2026-04-15 22:41; UTC

Uždarbis

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

2026-04-15 22:38; UTC

Uždarbis

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

2026-04-15 22:15; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-15 22:15; UTC

Rinkos pokalbiai

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

2026-04-15 22:14; UTC

Uždarbis

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

2026-04-15 22:12; UTC

Uždarbis

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

2026-04-15 22:11; UTC

Uždarbis

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

2026-04-15 22:11; UTC

Uždarbis

Lens Technology Swings to Loss in 1Q>300433.SZ

2026-04-15 22:07; UTC

Uždarbis

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

2026-04-15 21:34; UTC

Įsigijimai, susijungimai, perėmimai

Skild AI Acquires Zebra Technologies' Robotics Automation Business

2026-04-15 21:29; UTC

Karštos akcijos

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

2026-04-15 20:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2026-04-15 20:30; UTC

Uždarbis

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

2026-04-15 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-15 20:06; UTC

Rinkos pokalbiai

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

2026-04-15 19:46; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

2026-04-15 19:25; UTC

Rinkos pokalbiai

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

2026-04-15 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

2026-04-15 18:58; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

2026-04-15 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

2026-04-15 17:45; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

2026-04-15 16:58; UTC

Uždarbis

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

2026-04-15 16:52; UTC

Uždarbis

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

2026-04-15 16:46; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

2026-04-15 16:37; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

54.86% į viršų

12 mėnesių prognozė

Vidutinis 131.41 USD  54.86%

Aukščiausias 175 USD

Žemiausias 90 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

167 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat